Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients

Pivotal trials showed good clinical efficiency of the monoclonal antibody ocrelizumab while being well tolerated and manageable in multiple sclerosis (MS). However, data on adverse events in everyday practice are scarce. Hence, our study aims at investigating short-term tolerability of ocrelizumab in a “real-world” setting.

Source: Journal of the Neurological Sciences - June 10, 2020 Category: Neurology Authors: Victoria Prockl, Florian T. Nickel, Kathrin S. Utz, Kilian Fr öhlich, Tobias Engelhorn, Max-Josef Hilz, De-Hyung Lee, Ralf A. Linker, Konstantin Huhn Source Type: research